€106.90
1.86% yesterday
Borsa Italiana, Nov 15, 05:30 pm CET
ISIN
IT0003492391
Symbol
DIA
Sector

DiaSorin S.p.A. Stock price

€107.10
+3.70 3.58% 1M
+5.95 5.88% 6M
+13.86 14.86% YTD
+17.68 19.77% 1Y
-81.85 43.32% 3Y
-3.60 3.25% 5Y
+75.43 238.14% 10Y
Borsa Italiana, Closing price Fri, Nov 15 2024
+2.15 2.05%
ISIN
IT0003492391
Symbol
DIA
Sector

Key metrics

Market capitalization €5.71b
Enterprise Value €6.50b
P/E (TTM) P/E ratio 34.92
EV/FCF (TTM) EV/FCF 24.19
EV/Sales (TTM) EV/Sales 5.60
P/S ratio (TTM) P/S ratio 4.92
P/B ratio (TTM) P/B ratio 3.53
Dividend yield 1.10%
Last dividend (FY23) €1.15
Revenue growth (TTM) Revenue growth -7.27%
Revenue (TTM) Revenue €1.16b
EBIT (operating result TTM) EBIT €246.85m
Free Cash Flow (TTM) Free Cash Flow €268.64m
EPS (TTM) EPS €3.07
P/E forward 31.60
P/S forward 4.70
EV/Sales forward 5.36
Show more

Is DiaSorin S.p.A. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.

DiaSorin S.p.A. Stock Analysis

Unlock Scores for Free

Analyst Opinions

15 Analysts have issued a DiaSorin S.p.A. forecast:

6x Buy
40%
8x Hold
53%
1x Sell
7%

Analyst Opinions

15 Analysts have issued a DiaSorin S.p.A. forecast:

Buy
40%
Hold
53%
Sell
7%

Financial data from DiaSorin S.p.A.

Income Statement P&L | Balance Sheet | Cash Flow


TTM Annually
Jun '24
+/-
%
1,161 1,161
7% 7%
100%
- Direct Costs 464 464
3% 3%
40%
697 697
10% 10%
60%
- Selling and Administrative Expenses 226 226
4% 4%
19%
- Research and Development Expense 88 88
9% 9%
8%
383 383
14% 14%
33%
- Depreciation and Amortization 137 137
1% 1%
12%
EBIT (Operating Income) EBIT 247 247
20% 20%
21%
Net Profit 168 168
11% 11%
14%

In millions EUR.

Don't miss a Thing! We will send you all news about DiaSorin S.p.A. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

DiaSorin SpA engages in the development, production, and marketing of reagent kits for in vitro diagnostics. It specializes in the provision of immunodiagnostics and molecular diagnostics solutions which meet the needs of the following clinical areas: infectious diseases, cardiac markers, bone metabolism, hepatitis & retrovirus, oncology and endocrinology. The company was founded in 1968 and is headquartered in Vercelli, Italy.

Head office Italy
CEO Carlo Rosa
Employees 3,233
Founded 1968
Website www.diasorin.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today